Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin

Chronic Myelogenous Leukemia, Version 1.2014

(2017) Susan O’Brien et al.   Journal of the National Comprehensive Cancer Network

Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents

(2016) V. Escudero-Vilaplana et al.   EUROPEAN JOURNAL OF CANCER CARE

A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib

(2016) Ferdows Atiq et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Drug–drug interactions with imatinib

(2016) Isabelle Récoché et al.   MEDICINE

Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension

(2015) Didier Renard et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia

(2014) Kazuaki Taguchi et al.   PEDIATRICS INTERNATIONAL

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Twelve-Month Frequency of Drug-Metabolizing Enzyme and Transporter-Based Drug-Drug Interaction Potential in Patients Receiving Oral Enzyme-Targeted Kinase Inhibitor Antineoplastic Agents

(2013) Steven J. Bowlin et al.   MAYO CLINIC PROCEEDINGS

Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting

(2012) Edgar Faber et al.   ANNALS OF HEMATOLOGY

Enzyme induction with antiepileptic drugs: Cause for concern?

(2012) Martin J. Brodie et al.   EPILEPSIA

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial

(2012) F. Guilhot et al.   HAEMATOLOGICA

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

(2012) B Hanfstein et al.   LEUKEMIA

Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method

(2011) Roelof WF van Leeuwen et al.   BMC CANCER

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

(2011) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia

(2011) Sang Kyun Sohn et al.   LEUKEMIA & LYMPHOMA

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

(2010) A. Haouala et al.   BLOOD

Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic-Phase Chronic Myeloid Leukemia

(2010) N Takahashi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

(2010) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia

(2009) D. Milojkovic et al.   CLINICAL CANCER RESEARCH

Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia

(2009) Tatsuya Kawaguchi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels

(2008) Donna L. Forrest et al.   LEUKEMIA RESEARCH